The estimated Net Worth of David M. Spencer is at least $2.07 Million dollars as of 4 September 2018. David Spencer owns over 10,000 units of Bellicum Pharmaceuticals Inc stock worth over $6,723 and over the last 10 years David sold BLCM stock worth over $2,065,595.
David has made over 17 trades of the Bellicum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently David sold 10,000 units of BLCM stock worth $70,400 on 4 September 2018.
The largest trade David's ever made was selling 40,000 units of Bellicum Pharmaceuticals Inc stock on 18 July 2018 worth over $305,200. On average, David trades about 6,333 units every 44 days since 2014. As of 4 September 2018 David still owns at least 89,939 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of David Spencer stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON, TX, 77030.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., and Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: